Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 03, 2023 19:30 ET
|
Replimune Group Inc
WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2023 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
September 19, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
August 03, 2023 08:00 ET
|
Replimune Group Inc
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License...
Replimune to Present at Two Upcoming Investor Conferences
August 01, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Announces Sander Slootweg will Depart from its Board of Directors
July 20, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
June 06, 2023 10:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
June 05, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2023 14:15 ET
|
Replimune Group Inc
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no...
Replimune to Present at the Jefferies Global Healthcare Conference
June 01, 2023 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...